tiprankstipranks
Entera Bio Highlights Q3 2024 Financials and FDA Anticipation
Company Announcements

Entera Bio Highlights Q3 2024 Financials and FDA Anticipation

Don't Miss our Black Friday Offers:

Entera Bio ( (ENTX) ) just unveiled an announcement.

Entera Bio Ltd., a leader in oral peptide development, reported Q3 2024 financial results and business updates, highlighting advancements in their oral PTH(1-34) tablet, EB613, for osteoporosis. The company is anticipating a pivotal FDA ruling on osteoporosis drugs, which could enhance their treatment’s standing. Entera is also progressing with other oral therapies, like GLP-1/glucagon for obesity and GLP-2 for short bowel syndrome, using their proprietary N-Tab™ platform. Financially, Entera reported a net loss of $3 million with sufficient cash to fund operations into Q3 2025.

See more insights into ENTX stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyEntera Bio, Opko Health provide update on PK/PD results of GLP-1/Glucagon
TipRanks Auto-Generated NewsdeskEntera Bio Clarifies Non-Binding Information Disclosure
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App